Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado's A2B and A2A Receptor Antagonists and Cancer Vaccines

Core Insights - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics presented preclinical findings at the Society for Immunotherapy of Cancer Annual Meeting, highlighting the potential of combining selective adenosine A2B and A2A antagonists with cancer vaccines to enhance immune response [1][2][3] Research Findings - The studies conducted by the National Cancer Institute demonstrated that the combination of TT-4 (A2B antagonist) and TT-10 (A2A antagonist) with therapeutic vaccines resulted in significant tumor growth suppression and improved survival rates in mouse models [2] - In the TC1 lung cancer model, the triple combination of TT-4, TT-10, and an E7 peptide vaccine led to complete tumor regression in several mice, showcasing the potential for these treatments to translate to human applications [2] Clinical Development Status - TT-4 is an IND-enabled program with mesothelioma as the lead indication, preparing for first-patient dosing in Q1 2026 [4] - TT-10 is currently undergoing Phase 1 dose escalation trials in patients with advanced solid tumors [4] Strategic Goals - The collaboration with NCI reflects a long-term effort to enhance vaccine-driven immunity through the co-administration of selective receptor antagonists [3] - AlphaTON aims to leverage these preclinical data to guide capital deployment and partnerships for advancing TT-4 and TT-10 in clinical settings [3][10]